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Screening for Medullary Thyroid Cancer in France: A National Effort
Claude Calmettes,* A. Chaventre,* Nicole Feingold,* Brigitte Franc,*, J.M. Guliana,^
and the French Medullary Study Group (GETC)

Screening for medullary thyroid cancer (MTC) in France is based on a protocol that has been widely
distributed nationally. A network of coordinators utilizing a common questionnaire provides for an
effective national screening program. Calcitonin stimulation procedures are systematically used for
aU first-degree relatives of MTC patients. Pathological studies utilize special immunopathologic
techniques. Genealogic informaiion is obtained on aU index ca.ses, and blood specimens are collected
for establishing permanent ceU lines. The data collected are used not only to establish the diagnosis of
the hereditary or sporadic form ofthe disease bul also to expand the .screening as appropriate. This
common protocol has benefited patients and their families by improving early detection of cases,
increasing the number offamilies available for follow-up, and improving the prognosis ofthis cancer
Studies on these families have contributed significantly to the localization ofthe multiple endocrine
neoplasia type 2 gene. (HenryFordHospMedJ 1989;37:120-1)

ince the creation of the Groupe d'Etude des Tumeurs a Calcitonine (GETC) in 1983, efforts of this French Medullary
Study group have been directed toward improving methods of
screening families to detect new medullary thyroid cancer
(MTC) cases and gene carriers. The tools for screening, which
have been described previously (1-3), include a nationwide network of coordinators utilizing standard questionnaires, a central
registry, stimulated calcitonin (CT) tesfing, and standard pathological studies using immunopathologic techniques.

S

Resuhs of Screening for MTC in France
Cases collected in the tast 20 years have increased to a total of
1,377, including 349 hereditary cases found in 93 families
(Table). The procedures organized by the GETC have provided
data that have allowed more precise diagnoses at eariier stages
by ufilizing monoclonal CT assays, which have even permitted
diagnosis of MTC by using stored frozen plasma from family
members who had not been thought to be affected. Our experience has been similar to that of Ponder et al (4) in that the lack of
a posirive family history is inadequate to diagnose sporadic
MTC without famity screening. However, famity screening is at
fimes inconclusive because of the small number of relatives
available for testing or the lack of pathology data, or because CT
tesfing provides onty borderiine resutts occasionally even when
using a monoclonal anfibody in the assay. These national collaborafive studies have contributed significantly to the early detecfion of and better prognosis for MTC patients (5).
Genealogical studies have allowed us to connect certain families and their branches from different geographical areas
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through common ancestors (Figure). These studies have been
helpful in differentiating hereditary from sporadic cases (6).
Immunochemical CT studies offissuesections have established the diagnosis of MTC in some atypical forms (7,8), and
the bilateral MTC and C-cell hyperplasia have suggested the heTable
Medullary Thyroid Cancer in France, 1969-1988:
1,377 Cases*
Apparently sporadic: 1.028 cases
MTC only: 979 cases
MEN 2A: 20 cases
—3 MTC and HPT
—17 MTC and Pheo (Ist sign: 8 MTC and 9 Pheo)
MEN 2B: 29 cases
—5 Hirschsprung Pseudosyndrome
—24 Gorlin syndrome
Hereditary: 349 cases (93 families)
MTC only: 43 cases
MEN 2A: 45 cases
MEN 2B: 5 cases
•"Estimation as ofOctober 1989.
MTC = medullary thyroid cancer, HPT = hyperparathyroidism, Pheo
pheochromocytoma.
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reditary nature of the disease in certain cases (9). Thyrogtobulin
positivity in singte cells or in glandular- or folticular-tike pattems has been frequently encountered in hereditary cases (8),
but this finding does not seem to be a differentiating feature between hereditary and sporadic MTC. A prospective study of 34
MTC cases with somatostatin immunostaining also did not discriminate between hereditary and sporadic cases nor provide
prognostic data.
The availability of the targe families detected by the GETC
collaborative studies (5) has provided much clinical materiat for
genefic linkage studies and has helped confirm the location of
the gene for the multiple endocrine neoplasia type 2 (MEN 2)
syndrome to the pericentromeric area of chromosome 10 (10).
These molecular biology techniques have been apptied to the detection of MEN 2 gene carriers (11) and witt eventually hetp tead
to discovering the nature of the gene or genes invotved in causing MTC and the other tumors of the MEN 2 syndrome.
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Figure—Map with the number of French departments showing
the distribution of affected branches of family 5 from its origin in
central France.
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